Anemia in PD Patients

  • A. Rastogi
  • I.C. Macdougall
  • A.R. Nissenson

The prevalence of anemia and the use of erythropoiesis stimulating agents (ESAs) and parenteral iron in peritoneal dialysis patients have consistently been less than that seen in hemodialysis patients [1]. Most relevant data in this area is available from the United States and the USRDS and CMS ESRD Clinical Performance Measures project (CMS CPM project). Trends reported by the USRDS through calendar year 2004 show lower mean hemoglobin, lower EPO doses, and less use of parenteral iron therapy in peritoneal, compared to hemodialysis patients [1]. These facts are reflected in the economic data, only available through 2002. From 1998 through 2002, the annual Medicare payments for ESAs per patient on hemodialysis rose from $4,389 to $6,159, while for patients on peritoneal dialysis the Medicare payments were only $1,839 in $1998 and $3,074 in 2002.


Hemodialysis Patient Peritoneal Dialysis Patient Darbepoetin Alfa Intravenous Iron Iron Sucrose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    U.S. Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2006.Google Scholar
  2. 2.
    U.S. Renal Data System, USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2004.Google Scholar
  3. 3.
    Centers for Medicare & Medicaid Services. 2005 Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards & Quality, Baltimore, Maryland, December 2005.Google Scholar
  4. 4.
    Centers for Medicare & Medicaid Services. 2005 Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards & Quality, Baltimore, Maryland, September 2007.Google Scholar
  5. 5.
    Kaushansky K, Karplus PA. Hematopoietic growth factors: understanding functional diversity in structural terms. Blood 1993; 82: 3229–3240.PubMedGoogle Scholar
  6. 6.
    Sasaki H, Ochi N, Dell A, Fukuda M. Site-specific glycosylation of human recombinant erythropoietin: analysis of glycopeptides or peptides at each glycosylation site by fast atom bombardment mass spectrometry. Biochemistry 1988; 27: 8618–8626.PubMedCrossRefGoogle Scholar
  7. 7.
    Sasaki H, Bothner B, Dell A, Fukuda M. Carbohydrate structure of erythropoietin expressed in Chinese hamster ovary cells by a human erythropoietin cDNA. J Biol Chem 1987; 262: 12059–12076.PubMedGoogle Scholar
  8. 8.
    Rahbek-Nielsen H, Roepstorff P, Reischl H, et al. Glycopeptide profiling of human urinary erythropoietin by matrix-assisted laser desorption/ionization mass spectrometry. J Mass Spectrom 1997; 32: 948–958.PubMedCrossRefGoogle Scholar
  9. 9.
    Dordal MS, Wang FF, Goldwasser E. The role of carbohydrate in erythropoietin action. Endocrinology 1985; 116: 2293–2299.PubMedCrossRefGoogle Scholar
  10. 10.
    Weikert S, Papac D, Briggs J, et al. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat Biotechnol 1999; 17: 1116–1121.PubMedCrossRefGoogle Scholar
  11. 11.
    Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 1989; 73: 90–99.PubMedGoogle Scholar
  12. 12.
    Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84: 3–10.PubMedCrossRefGoogle Scholar
  13. 13.
    Elliott S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 2003; 21: 414–421.PubMedCrossRefGoogle Scholar
  14. 14.
    Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant. 2001; 16 (suppl. 3): 3–13.PubMedGoogle Scholar
  15. 15.
    Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem 2003; 278 (22): 19575–19578.PubMedCrossRefGoogle Scholar
  16. 16.
    Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004; 5: 343–354.PubMedCrossRefGoogle Scholar
  17. 17.
    Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 2004; 286: R977–R988.PubMedGoogle Scholar
  18. 18.
    D'Andrea AD, Zon LI. Erythropoietin receptor. Subunit structure and activation. J Clin Invest 1990; 86: 681–687.PubMedCrossRefGoogle Scholar
  19. 19.
    Youssoufian H, Longmore G, Neumann D, et al. Structure, function, and activation of the erythropoietin receptor. Blood 1993; 81: 2223–2236.PubMedGoogle Scholar
  20. 20.
    Grodberg J, Davis KL, Sykowski AJ. Alanine scanning mutagenesis of human erythropoietin identifies four amino acids which are critical for biological activity. Eur J Biochem 1993; 218: 597–601.PubMedCrossRefGoogle Scholar
  21. 21.
    Boissel JP, Lee WR, Presnell SR, et al. Erythropoietin structure-function relationships. Mutant proteins that test a model of tertiary structure. J Biol Chem 1993; 268: 15983–15993.PubMedGoogle Scholar
  22. 22.
    Elliott S, Lorenzini T, Chang D, Barzilay J, et al. Fine-structure epitope mapping of antierythropoietin monoclonal antibodies reveals a model of recombinant human erythropoietin structure. Blood 1996; 87: 2702–2713.PubMedGoogle Scholar
  23. 23.
    Qiu H, Belanger A, Yoon HW, Bunn HF. Homodimerization restores biological activity to an inactive erythropoietin mutant. J Biol Chem 1998; 273: 11173–11176.PubMedCrossRefGoogle Scholar
  24. 24.
    Elliott S, Lorenzini T, Chang D, et al. Mapping of the active site of recombinant human erythropoietin. Blood 1997; 89: 493–502.PubMedGoogle Scholar
  25. 25.
    Jelkmann W. The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 2002; 69 (5–6): 265–274.PubMedCrossRefGoogle Scholar
  26. 26.
    Koury MJ, Bondurant MC. The mechanism of erythropoietin action. Am J Kidney Dis 1991; 18 (4 suppl. 1): 20–23.PubMedGoogle Scholar
  27. 27.
    Suzuki N, Suwabe N, Ohneda O, et al. Identification and characterization of 2 types of erythroid progenitors that express GATA-1 at distinct levels. Blood 2003; 102: 3575–3583.PubMedCrossRefGoogle Scholar
  28. 28.
    Chiba T, Ikawa Y, Todokoro K. GATA-1 transactivates erythropoietin receptor gene, and erythropoietin receptor-mediated signals enhance GATA-1 gene expression. Nucleic Acids Res 1991; 19: 3843–3848.PubMedCrossRefGoogle Scholar
  29. 29.
    De Maria R, Zeuner A, Eramo A, et al. Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1. Nature 1999; 401: 489–493.PubMedCrossRefGoogle Scholar
  30. 30.
    Gregory T, Yu C, Ma A, et al. GATA-1 and erythropoietin cooperate to promote erythroid cell survival by regulating bcl-xL expression. Blood 1999; 94: 87–96.PubMedGoogle Scholar
  31. 31.
    Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003; 102: 783–788.PubMedCrossRefGoogle Scholar
  32. 32.
    Ganz T. Molecular control of iron transport. J Am Soc Nephrol 2007; 18: 394–400.PubMedCrossRefGoogle Scholar
  33. 33.
    Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011.PubMedCrossRefGoogle Scholar
  34. 34.
    Macdougall IC, Lewis NP, Saunders MJ, et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990; 335: 489–493.PubMedCrossRefGoogle Scholar
  35. 35.
    Mayer G, Thum J, Cada EM, et al. Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 1988; 34: 525–528.PubMedCrossRefGoogle Scholar
  36. 36.
    Keown PA. Quality of life in end-stage renal disease patients during recombinant human erythropoietin therapy. Contrib Nephrol 1991; 88: 81–86.PubMedGoogle Scholar
  37. 37.
    Marsh JT, Brown WS, Wolcott D., et al. rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 1991; 39: 155–163.PubMedCrossRefGoogle Scholar
  38. 38.
    Nissenson AR. Epoetin and cognitive function. Am J Kidney Dis 1992; 20 (suppl. 1): 21–24.PubMedGoogle Scholar
  39. 39.
    Moia M, Mannucci PM, Vizzotto L, et al. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987; ii: 1227–1229.CrossRefGoogle Scholar
  40. 40.
    Levin A, Singer J, Thompson CR, et al. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 1996; 34: 125–134.CrossRefGoogle Scholar
  41. 41.
    Mann JF. What are the short-term and long-term consequences of anaemia in CRF patients? Nephrol Dial Transplant 1999; 14 (suppl. 2): 29–36.PubMedCrossRefGoogle Scholar
  42. 42.
    Neff MS, Kim KE, Persoff M, et al. Hemodynamics of uremic anemia. Circulation 1971; 43: 867–883.Google Scholar
  43. 43.
    Himelman RB, Landzberg JS, Simonson JS, et al. Cardiac consequences of renal transplantation: changes in left ventricular morphology and function. J Am Coll Cardiol 1988; 12: 915–923.PubMedCrossRefGoogle Scholar
  44. 44.
    Besarab A, Kline Bolton W, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584–590.PubMedCrossRefGoogle Scholar
  45. 45.
    Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180–2189.PubMedCrossRefGoogle Scholar
  46. 46.
    Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 335: 2071–2084.CrossRefGoogle Scholar
  47. 47.
    Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006; 335: 2085–2098.CrossRefGoogle Scholar
  48. 48.
    Löw-Friedrich I, Grützmacher P, März W, et al. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 1991; 11: 54–60.PubMedCrossRefGoogle Scholar
  49. 49.
    Duke M, Abelmann WH. The hemodynamic response to chronic anemia. Circulation 1969; 39: 503–515.PubMedGoogle Scholar
  50. 50.
    Teruel JL, Pascual J, Jiménez M, et al. Hemodynamic changes in hemodialyzed patients during treatment with recombinant human erythropoietin. Nephron 1991; 58: 135–137.PubMedCrossRefGoogle Scholar
  51. 51.
    Edmunds ME, Walls J, Tucker B, et al. Seizures in haemodialysis patients treated with recombinant human erythropoietin. Nephrol Dial Transplant 1989; 4: 1065–1069.PubMedGoogle Scholar
  52. 52.
    Macdougall IC, Davies ME, Hutton RD, et al. Rheological studies during treatment of renal anaemia with recombinant human erythropoietin. Br J Haematol 1991; 77: 550–558.PubMedCrossRefGoogle Scholar
  53. 53.
    Furuland H, Linde T, Ahlmen J, et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003; 18: 353–361.PubMedCrossRefGoogle Scholar
  54. 54.
    Fernandez A, Vega N, Jimenez F, Macia M, Laraudiogoitia E, Hortal L, Perdomo M, Plaza C, Rodriguez JC, Palop L. Effect of recombinant human erythropoietin treatment on hemodynamic parameters in continuous ambulatory peritoneal dialysis and hemodialysis patients. Am J Nephrol 1992; 12: 207–211.PubMedCrossRefGoogle Scholar
  55. 55.
    Viganó G, Benigni A, Mendogni D, et al. Recombinant human erythropoietin to correct uremic bleeding. Am J Kidney Dis 1991; 18: 44–49.PubMedGoogle Scholar
  56. 56.
    Macdougall IC, Davies ME, Hallett I, et al. Coagulation studies and fistula blood flow during erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 1991; 6: 862–867.PubMedGoogle Scholar
  57. 57.
    Taylor JE, McLaren M, Henderson IS, et al. Prothrombotic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant 1992; 7: 235–239.PubMedGoogle Scholar
  58. 58.
    Huraib S, Al-Momen AK, Gader AMA, et al. Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients. Clin Nephrol 1991; 36: 252–257.PubMedGoogle Scholar
  59. 59.
    Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, et al. Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 2000; 11: 335–342.PubMedGoogle Scholar
  60. 60.
    Schaefer RM, Kokot F, Wernze H, et al. Improved sexual function in hemodialysis patients on recombinant erythropoietin: a possible role for prolactin. Clin Nephrol 1989; 31: 1–5.PubMedGoogle Scholar
  61. 61.
    Bommer J, Kugel M, Schwöbel B, et al. Improved sexual function during recombinant human erythropoietin therapy. Nephrol Dial Transplant 1990; 5: 204–207.PubMedGoogle Scholar
  62. 62.
    Gladziwa U, Dakshinamurty KV, Mann H, Siebert H-G. Pregnancy in a dialysis patient under recombinant human erythropoietin. Clin Nephrol 1992; 37: 215.PubMedGoogle Scholar
  63. 63.
    Kokot F, Wiecek A, Grzeszczak W, et al. Influence of erythropoietin treatment on endocrine abnormalities in haemodialyzed patients. Contrib Nephrol 1989; 76: 257–272.PubMedGoogle Scholar
  64. 64.
    Bárány P, Fehrman I, Godoy C. Long-term effects on lymphocytotoxic antibodies and immune reactivity in hemodialysis patients treated with recombinant human erythropoietin. Clin Nephrol 1992; 37: 90–96.PubMedGoogle Scholar
  65. 65.
    Sennesael JJ, Van Der Niepen P, Verbeelen D. Treatment with recombinant human erythropoietin increases antibody titers after hepatitis B vaccination in dialysis patients. Kidney Int 1991; 40: 121–128.PubMedCrossRefGoogle Scholar
  66. 66.
    Veys N, Vanholder R, Ringoir S. Correction of deficient phagocytosis during erythropoietin treatment in maintenance hemodialysis patients. Am J Kidney Dis 1992; 19: 358–363.PubMedGoogle Scholar
  67. 67.
    De Marchi S, Cecchin E, Villalta D, et al. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 1992; 326: 969–974.PubMedCrossRefGoogle Scholar
  68. 68.
    Lubrich-Birkner I, Schollmeyer P, Steinhauer HB. One year experience with subcutaneous human erythropoietin in CAPD: correction of renal anemia and increased ultrafiltration. Adv Perit Dial 1990; 6: 302–307.PubMedGoogle Scholar
  69. 69.
    IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 2001; 37: S182–S238.CrossRefGoogle Scholar
  70. 70.
    Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 (suppl. 2): ii1–ii47.PubMedCrossRefGoogle Scholar
  71. 71.
    NICE (2006). Anaemia Management in Chronic Kidney Disease. Clinical Guideline 039. Royal College of Physicians, London.Google Scholar
  72. 72.
    KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47 (suppl. 3): S11–S145.Google Scholar
  73. 73.
    National Kidney Foundation. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50: 471–530.CrossRefGoogle Scholar
  74. 74.
    Macdougall IC. Individualizing target haemoglobin concentrations – Tailoring treatment for renal anaemia. Nephrol Dial Transplant 2001; 16 (suppl. 7): 9–14.PubMedGoogle Scholar
  75. 75.
    Caro J, Brown S, Miller O, et al. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 1979; 93: 449–458.PubMedGoogle Scholar
  76. 76.
    Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977; 252: 5558–5564.PubMedGoogle Scholar
  77. 77.
    Lin FK, Suggs S, Lin CH et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985; 82: 7580–7584.Google Scholar
  78. 78.
    Winearls CG, Oliver DO, Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175–1178.PubMedCrossRefGoogle Scholar
  79. 79.
    Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73–78.PubMedCrossRefGoogle Scholar
  80. 80.
    Bommer J, Barth HP, Zeier M, et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 1991; 88: 136–143.PubMedGoogle Scholar
  81. 81.
    Macdougall IC, Roberts DE, Neubert P, et al. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet. 1989; 1: 425–427.PubMedCrossRefGoogle Scholar
  82. 82.
    Macdougall IC, Roberts DE, Coles GA, et al. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet 1991; 20: 99–113.PubMedCrossRefGoogle Scholar
  83. 83.
    Grzeszczak W, Sulowicz W, Rutkowski B, et al. The efficacy and safety of weekly and fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant 2005; 20: 936–944.PubMedCrossRefGoogle Scholar
  84. 84.
    Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis patients. N Engl J Med 1998; 339: 578–583.PubMedCrossRefGoogle Scholar
  85. 85.
    Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 439–446.PubMedCrossRefGoogle Scholar
  86. 86.
    Weiss LG, Clyne N, Divino Fihlho J, et al. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin beta: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 2000; 15: 2014–2019.PubMedCrossRefGoogle Scholar
  87. 87.
    Locatelli F, Baldamus CA, Villa G, et al. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis 2002; 40: 119–125.PubMedCrossRefGoogle Scholar
  88. 88.
    Egrie JC, Grant JR, Gillies DK, et al. The role of carbohydrate on the biological activity of erythropoietin. Glycoconj J 1993; 10: 263.CrossRefGoogle Scholar
  89. 89.
    Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999; 10: 2392–2395.PubMedGoogle Scholar
  90. 90.
    Padhi D, Ni L, Cooke B, et al. An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. Clin Pharmacokinet 2006; 45: 503–510PubMedCrossRefGoogle Scholar
  91. 91.
    Vanrenterghem Y, Barany P, Mann JF, et al. European/Australian NESP 970200 Study Group. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002; 62: 2167–2175.PubMedCrossRefGoogle Scholar
  92. 92.
    Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 110–118.PubMedCrossRefGoogle Scholar
  93. 93.
    Jadoul M, Vanrenterghem Y, Foret M et al. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 2004; 19: 898–903.PubMedCrossRefGoogle Scholar
  94. 94.
    Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005; 4: 436–440.PubMedGoogle Scholar
  95. 95.
    Macdougall IC, Robson R, Opatrna S, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 1211–1215.PubMedCrossRefGoogle Scholar
  96. 96.
    Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC; BA 16528 Study Investigators. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. Clin Nephrol 2007; 67: 306–317.PubMedGoogle Scholar
  97. 97.
    Locatelli F, Villa G, Arias M, et al. on behalf of the BA16286 study group. CERA (Continuous Erythropoietin Receptor Activator) maintains hemoglobin levels in dialysis patients when administered subcutaneously up to once every 4 weeks. J Am Soc Nephrol 2004; 15: 543A.CrossRefGoogle Scholar
  98. 98.
    Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006; 368 (9539): 947–953.PubMedCrossRefGoogle Scholar
  99. 99.
    Fan Q, Leuther KK, Holmes CP, et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006; 34: 1303–1311.PubMedCrossRefGoogle Scholar
  100. 100.
    Maxwell P. HIF-1: an oxygen response system with special relevance to the kidney. J Am Soc Nephrol 2003; 14: 2712–2722.PubMedCrossRefGoogle Scholar
  101. 101.
    Wiecek A, Piecha G, Ignacy W, et al. Pharmacological stabilization of HIF increases hemoglobin concentration in anemic patients with chronic kidney disease. Nephrol Dial Transplant 2005; 20 (suppl. 5): v195.Google Scholar
  102. 102.
    Macdougall IC. Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opin Nephrol Hypertens 1994; 3: 620–625.PubMedCrossRefGoogle Scholar
  103. 103.
    Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 1995; 26: 41–46.PubMedCrossRefGoogle Scholar
  104. 104.
    Macdougall IC, Tucker B, Thompson J, et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694–1699.PubMedCrossRefGoogle Scholar
  105. 105.
    Johnson DW, Herzig KA, Gissane R, et al. A prospective crossover trial comparing intermittent intravenous and continuous oral iron supplements in peritoneal dialysis patients. Nephrol Dial Transplant 2001; 16: 1879–1884.PubMedCrossRefGoogle Scholar
  106. 106.
    Pronai W, Riegler-Keil M, Silberbauer K, Stockenhuber F. Folic acid supplementation improves erythropoietin response. Nephron 1995; 71: 395–400.PubMedCrossRefGoogle Scholar
  107. 107.
    Zachee P, Chew SL, Daelemans R, et al. Erythropoietin resistance due to vitamin B12 deficiency. Case report and retrospective analysis of B12 levels after erythropoietin treatment. Am J Nephrol 1992; 12: 188–191.PubMedCrossRefGoogle Scholar
  108. 108.
    Mydlik M, Derzsiova K. Erythrocyte vitamins B1, B2 and B6 and erythropoietin. Am J Nephrol 1993; 13: 464–466.PubMedCrossRefGoogle Scholar
  109. 109.
    Gastaldello K, Vereerstraeten A, Nzame-Nze T, et al. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 1995; 10 (suppl. 6): 44–47.PubMedGoogle Scholar
  110. 110.
    Tarng DC, Huang, TP. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol Dial Transplant 1998; 13: 2867–2872.PubMedCrossRefGoogle Scholar
  111. 111.
    Albitar S, Genin R, Fen-Chong M, et al. High-dose alfacalcidol improves anaemia in patients on haemodialysis. Nephrol Dial Transplant 1997; 12: 514–518.PubMedCrossRefGoogle Scholar
  112. 112.
    Goicoechea M, Vazquez MI, Ruiz MA, et al. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients. Nephron 1998; 78: 23–27.PubMedCrossRefGoogle Scholar
  113. 113.
    Kooistra MP, Struyvenberg A, van Es A. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels. Nephron 1991; 57: 127–128.PubMedCrossRefGoogle Scholar
  114. 114.
    Labonia WD. L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis 1995; 26: 757–764.PubMedCrossRefGoogle Scholar
  115. 115.
    Ballal SH, Domoto DT, Polack DC, et al. Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis 1991; 17: 29–33.PubMedGoogle Scholar
  116. 116.
    Gaughan WJ, Liss KA, Dunn SR, et al. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients. Am J Kidney Dis 1997; 30: 495–500.PubMedCrossRefGoogle Scholar
  117. 117.
    Navarro JF, Mora C, Macia M, Garcia J. Randomized prospective comparison between erythropoietin and androgens in CAPD patients. Kidney Int 2002; 61: 1537–1544.PubMedCrossRefGoogle Scholar
  118. 118.
    Brox AG, Zhang F, Guyda H, Gagnon RF. Subtherapeutic erythropoietin and insulin-like growth factor-1 correct the anemia of chronic renal failure in the mouse. Kidney Int 1996; 50: 937–943.PubMedCrossRefGoogle Scholar
  119. 119.
    Macdougall IC. Hyporesponsiveness to anemia therapy – what are we doing wrong? Perit Dial Int 2001; 21 (suppl. 3): S225–S230.PubMedGoogle Scholar
  120. 120.
    Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 2007; 12: 321–330.CrossRefGoogle Scholar
  121. 121.
    Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004; 15: 398–406.PubMedCrossRefGoogle Scholar
  122. 122.
    Cavill I. The rejected reticulocyte. Br J Haematol 1993; 84: 563–565.PubMedCrossRefGoogle Scholar
  123. 123.
    Nicoletta P, Bernardini J, Dacko C, et al. Compliance with subcutaneous erythropoietin in peritoneal dialysis patients. Adv Perit Dial 2000; 16: 90–92.PubMedGoogle Scholar
  124. 124.
    Wazny LD, Stojimirovic BB, Heidenheim P, et al. Factors influencing erythropoietin compliance in peritoneal dialysis patients. Am J Kidney Dis 2002; 40: 623–628.PubMedCrossRefGoogle Scholar
  125. 125.
    Levin A. Understanding recent haemoglobin trials in CKD: Methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant 2007; 22: 309–312.PubMedCrossRefGoogle Scholar
  126. 126.
    Phrommintikul A, Haas SJ, Elsik M, et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381–388.PubMedCrossRefGoogle Scholar
  127. 127.
    Fishbane S. Iron treatment: impact of safety issues. Am J Kidney Dis 1998; 32 (suppl. 4): S152–S156.PubMedCrossRefGoogle Scholar
  128. 128.
    Deicher R, Ziai F, Cohen G, et al. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003; 64: 728–736.PubMedCrossRefGoogle Scholar
  129. 129.
    Hoen B, Paul-Dauphin A, Hestin D, Kessler M. EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869–876.PubMedGoogle Scholar
  130. 130.
    Rooyakkers TM, Stroes ES, Kooistra MP, et al: Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002; 32 (suppl. 1): 9–16.PubMedCrossRefGoogle Scholar
  131. 131.
    Agarwal R, Vasavada N, Sachs NG, et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279–2289.PubMedCrossRefGoogle Scholar
  132. 132.
    Zager RA, Johnson AC, Hanson SY, et al. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90–103.PubMedCrossRefGoogle Scholar
  133. 133.
    Leehey DJ, Palubiak DJ, Chebrolu S, et al. Sodium ferric gluconate causes oxidative stress but not acute renal injury in patients with chronic kidney disease: a pilot study. Nephrol Dial Transplant 2005; 20: 135–140.PubMedCrossRefGoogle Scholar
  134. 134.
    Scheiber-Mojdehkar B, Lutzky B, Schaufler R, et al. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: No correlation to peroxide generation. J Am Soc Nephrol 2004; 15: 1648–1655.PubMedCrossRefGoogle Scholar
  135. 135.
    Feldman HI, Joffe M, Robinson B, et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623–1632.PubMedCrossRefGoogle Scholar
  136. 136.
    Syed RS, Reid SW, Li C, Cheetham JC, Aoki KH, Liu B, Zhan H, Osslund TD, Chirino AJ, Zhang J, Finer-Moore J, Elliott S, Sitney K, Katz BA, Matthews DJ, Wendoloski JJ, Egrie J, Stroud RM. Efficiency of Signalling through cytokine receptors depends critically on receptor orientation, Nature 1998; 395: 511–516.PubMedCrossRefGoogle Scholar
  137. 137.
    Remy I, Wilson IA, Michnick SW. Erythropoietin receptor activation by a ligand-induced conformation change. Science 1999; 283: 990–993.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Department of Medicine, Division of NephrologyDavid Geffen School of Medicine at UCLALos AngelesUSA

Personalised recommendations